Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Living Cell Technologies Ltd. (OTC: LVCLF).

Full DD Report for LVCLF

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-13N/A0.0282N/AN/A0
2018-12-12N/A0.0282N/AN/A0
2018-12-110.03080.02820.03080.028213,000
2018-12-10N/A0.0307N/AN/A0
2018-12-07N/A0.0307N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0410,00010,000100.0000Short
2018-11-1580,000263,62230.3465Cover
2018-10-19200200100.0000Short
2018-08-1066,00066,000100.0000Short
2018-07-195,0005,000100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LVCLF.


About Living Cell Technologies Ltd. (OTC: LVCLF)

Logo for Living Cell Technologies Ltd. (OTC: LVCLF)

lt p gt Living Cell Technologies Limited LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercializing regenerative treatments which restore function using naturally occurring cells. LCT s lead product NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson s disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease modifying treatment for patients with Parkinson s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington s, Alzheimer s and motor neurone diseases. LCT s proprietary encapsulation technology, IMMUPEL, allows cell therapies to be used without the need for co treatment with drugs that suppress the immune system. LCT holds a interest in Diatranz Otsuka Limited which is developing a cell therapy for type diabetes. LCT is listed on the Australian ASX: LCT and US OTCQX: LVCLY stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand. lt /p gt

 

Contact Information

 

 

Current Management

  • Ken M Taylor / CEO
  • Mark Licciardo / Company Secretary Manager
  • John Cowan / Head of Finance
  • Kate Goland / Other
  • Roy Austin / Chairman
  • Laurie Hunter /
  • Bernard Tuch /
  • Robert Willcocks /

Current Share Structure

  • Market Cap: $11,771,684 - 03/09/2018
  • Issue and Outstanding: 571,440,981 - 01/29/2018

 


Recent Filings from (OTC: LVCLF)

Interim Financial Report - Half Yearly Reports and Financial Statements
Filing Type: Interim Financial Report - Half Yearly Reports and Financial StatementsFiling Source: OTC Markets
Filing Date: February, 22 2018
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: December, 29 2017

 

 


Daily Technical Chart for (OTC: LVCLF)

Daily Technical Chart for (OTC: LVCLF)


Stay tuned for daily updates and more on (OTC: LVCLF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: LVCLF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LVCLF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LVCLF and does not buy, sell, or trade any shares of LVCLF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/